Cargando…
A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions
Mesenchymal stem cells (MSCs) are classified as advanced therapy medicinal products, a new category of GMP (good manufacturing practice)-compliant medicines for clinical use. We isolated MSCs from 5 bone marrow (BM) samples using human platelet lysate (HPL) instead of foetal bovine serum (FBS). We u...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953582/ https://www.ncbi.nlm.nih.gov/pubmed/35328655 http://dx.doi.org/10.3390/ijms23063234 |
_version_ | 1784675886729003008 |
---|---|
author | Mareschi, Katia Marini, Elena Niclot, Alessia Giovanna Santa Banche Barone, Marta Pinnetta, Giuseppe Adamini, Aloe Spadea, Manuela Labanca, Luciana Lucania, Graziella Ferrero, Ivana Fagioli, Franca |
author_facet | Mareschi, Katia Marini, Elena Niclot, Alessia Giovanna Santa Banche Barone, Marta Pinnetta, Giuseppe Adamini, Aloe Spadea, Manuela Labanca, Luciana Lucania, Graziella Ferrero, Ivana Fagioli, Franca |
author_sort | Mareschi, Katia |
collection | PubMed |
description | Mesenchymal stem cells (MSCs) are classified as advanced therapy medicinal products, a new category of GMP (good manufacturing practice)-compliant medicines for clinical use. We isolated MSCs from 5 bone marrow (BM) samples using human platelet lysate (HPL) instead of foetal bovine serum (FBS). We used a new method of HPL production consisting of treating platelet (PLTs) pools with Ca-Gluconate to form a gel clot, then mechanically squeezing to release growth factors. We compared the new HPL (HPL-S) with the standard (HPL-E) obtained by freezing/thawing cycles and by adding heparin. HPL-S had not PLTs and fibrinogen but the quantity of proteins and growth factors was comparable to HPL-E. Therefore, HPL-S needed fewer production steps to be in compliance with GMP conditions. The number of colonies forming unit-fibroblasts (CFU-F) and the maintenance of stem markers showed no significant differences between MSCs with HPL-E and HPL-S. The cumulative population doubling was higher in MSCs with HPL-E in the earlier passages, but we observed an inverted trend of cell growth at the fourth passage. Immunophenotypic analysis showed a significant lower expression of HLA-DR in the MSCs with HPL-S (1.30%) than HPL-E (14.10%). In conclusion, we demonstrated that HPL-S is an effective alternative for MSC production under GMP conditions. |
format | Online Article Text |
id | pubmed-8953582 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89535822022-03-26 A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions Mareschi, Katia Marini, Elena Niclot, Alessia Giovanna Santa Banche Barone, Marta Pinnetta, Giuseppe Adamini, Aloe Spadea, Manuela Labanca, Luciana Lucania, Graziella Ferrero, Ivana Fagioli, Franca Int J Mol Sci Article Mesenchymal stem cells (MSCs) are classified as advanced therapy medicinal products, a new category of GMP (good manufacturing practice)-compliant medicines for clinical use. We isolated MSCs from 5 bone marrow (BM) samples using human platelet lysate (HPL) instead of foetal bovine serum (FBS). We used a new method of HPL production consisting of treating platelet (PLTs) pools with Ca-Gluconate to form a gel clot, then mechanically squeezing to release growth factors. We compared the new HPL (HPL-S) with the standard (HPL-E) obtained by freezing/thawing cycles and by adding heparin. HPL-S had not PLTs and fibrinogen but the quantity of proteins and growth factors was comparable to HPL-E. Therefore, HPL-S needed fewer production steps to be in compliance with GMP conditions. The number of colonies forming unit-fibroblasts (CFU-F) and the maintenance of stem markers showed no significant differences between MSCs with HPL-E and HPL-S. The cumulative population doubling was higher in MSCs with HPL-E in the earlier passages, but we observed an inverted trend of cell growth at the fourth passage. Immunophenotypic analysis showed a significant lower expression of HLA-DR in the MSCs with HPL-S (1.30%) than HPL-E (14.10%). In conclusion, we demonstrated that HPL-S is an effective alternative for MSC production under GMP conditions. MDPI 2022-03-17 /pmc/articles/PMC8953582/ /pubmed/35328655 http://dx.doi.org/10.3390/ijms23063234 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mareschi, Katia Marini, Elena Niclot, Alessia Giovanna Santa Banche Barone, Marta Pinnetta, Giuseppe Adamini, Aloe Spadea, Manuela Labanca, Luciana Lucania, Graziella Ferrero, Ivana Fagioli, Franca A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions |
title | A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions |
title_full | A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions |
title_fullStr | A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions |
title_full_unstemmed | A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions |
title_short | A New Human Platelet Lysate for Mesenchymal Stem Cell Production Compliant with Good Manufacturing Practice Conditions |
title_sort | new human platelet lysate for mesenchymal stem cell production compliant with good manufacturing practice conditions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953582/ https://www.ncbi.nlm.nih.gov/pubmed/35328655 http://dx.doi.org/10.3390/ijms23063234 |
work_keys_str_mv | AT mareschikatia anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT marinielena anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT niclotalessiagiovannasantabanche anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT baronemarta anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT pinnettagiuseppe anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT adaminialoe anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT spadeamanuela anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT labancaluciana anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT lucaniagraziella anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT ferreroivana anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT fagiolifranca anewhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT mareschikatia newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT marinielena newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT niclotalessiagiovannasantabanche newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT baronemarta newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT pinnettagiuseppe newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT adaminialoe newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT spadeamanuela newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT labancaluciana newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT lucaniagraziella newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT ferreroivana newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions AT fagiolifranca newhumanplateletlysateformesenchymalstemcellproductioncompliantwithgoodmanufacturingpracticeconditions |